このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Roche Holding 過去の業績

過去基準チェック /06

Roche Holdingの収益は年間平均-3.4%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間7.5% 0.04%割合で増加しています。 Roche Holdingの自己資本利益率は35%であり、純利益率は17.5%です。

主要情報

-3.4%

収益成長率

-1.7%

EPS成長率

Pharmaceuticals 業界の成長	16.3%
収益成長率	-0.02%
株主資本利益率	35.0%
ネット・マージン	17.5%
前回の決算情報	30 Jun 2024

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Feb 08

Recent updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

収支内訳

Roche Holding の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SWX:ROG 収益、費用、利益 ( )CHF Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	60,581	10,619	13,346	13,381
31 Mar 24	60,511	11,059	13,416	13,463
31 Dec 23	60,441	11,498	13,486	13,545
30 Sep 23	61,486	11,263	13,738	13,669
30 Jun 23	62,530	11,028	13,894	13,793
31 Mar 23	64,172	11,725	13,793	13,696
31 Dec 22	65,814	12,421	13,691	13,599
30 Sep 22	66,716	13,539	13,262	13,592
30 Jun 22	67,617	14,657	12,833	13,585
31 Mar 22	66,734	14,294	12,405	13,804
31 Dec 21	65,850	13,930	11,977	14,022
30 Sep 21	63,974	13,975	12,037	13,747
30 Jun 21	62,098	14,019	12,097	13,472
31 Mar 21	61,221	14,157	12,026	13,019
31 Dec 20	60,343	14,295	11,954	12,566
30 Sep 20	61,361	13,626	12,289	12,382
30 Jun 20	62,378	12,957	12,624	12,198
31 Mar 20	63,065	13,227	12,904	12,061
31 Dec 19	63,751	13,497	13,183	11,923
30 Sep 19	62,736	12,654	13,275	11,702
30 Jun 19	61,721	11,810	12,933	11,480
31 Mar 19	60,609	11,155	12,800	11,337
31 Dec 18	59,497	10,500	12,667	11,194
30 Sep 18	58,611	10,483	12,641	11,005
30 Jun 18	57,725	10,465	12,615	10,815
31 Mar 18	56,736	9,549	12,322	10,672
31 Dec 17	55,746	8,633	12,029	10,529
30 Sep 17	54,961	9,154	11,148	10,411
30 Jun 17	54,176	9,675	10,266	10,293
31 Mar 17	53,406	9,626	10,305	10,172
31 Dec 16	52,636	9,576	10,343	10,050
30 Sep 16	52,109	9,332	10,655	9,975
30 Jun 16	51,581	9,087	10,966	9,900
31 Mar 16	50,992	8,975	10,953	9,678
31 Dec 15	50,403	8,863	10,940	9,455
30 Sep 15	50,364	8,908	10,978	9,305
30 Jun 15	50,324	8,953	11,004	9,155
31 Mar 15	50,095	9,143	10,924	9,068
31 Dec 14	49,866	9,332	10,844	8,980
30 Sep 14	49,300	10,044	10,698	8,899
30 Jun 14	48,733	10,756	10,551	8,817
31 Mar 14	48,673	10,960	10,569	8,787
31 Dec 13	48,612	11,164	10,587	8,756

質の高い収益: ROGにはCHF3.8B } という大きな一回限りの損失があり、過去 12 か月の財務実績が30th June, 2024に影響を及ぼしています。

利益率の向上: ROGの現在の純利益率 (17.5%)は、昨年(17.6%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ROGの収益は過去 5 年間で年間3.4%減少しました。

成長の加速: ROGは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: ROGは過去 1 年間で収益成長率がマイナス ( -7.4% ) となったため、 Pharmaceuticals業界平均 ( 1.2% ) と比較することが困難です。

株主資本利益率

高いROE: ROGの自己資本利益率 ( 34.96% ) は高いですが、この指標は負債レベルが高いために歪んでいます。

Roche Holding 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First half 2024 earnings: EPS misses analyst expectations

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Recent updates

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings: EPS misses analyst expectations

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

過去基準チェック /06